Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma
Gareth Morgan et al.
Reducing the risk of secondary malignancies in lymphoma
Managing transplant ineligible AML patients
Smouldering myeloma: detection, risk stratification and defining a new standard of care